Key result
Antihypertensive therapy impacts patient quality of life across subjective well-being and general health dimensions.
Why the study?
Quality of life in healthcare should encompass the total impact of disease and treatment on emotional, physical, and social well-being, motivating an evaluation of the effects of antihypertensive pharmacotherapy on general well-being.
How does antihypertensive pharmacotherapy affect patients' general well-being and quality of life?
How does antihypertensive pharmacotherapy affect patients' general well-being and quality of life?
Answers are grounded in this paper and cite their sources.
This review discusses the conceptualization of quality of life and well-being in the context of antihypertensive treatment.
Quality of life is often considered to equate how the medical treatment is subjectively perceived by the patient, but ought to include the total impact of the disease/treatment on the patient's emotional, physical, and social well‐being. Recently, a proposal for a generally applicable definition of quality of life in health care was put forward. This definition includes general well‐being, health, and welfare (external factors), as three fundamental components, and the definition is based on both objective and subjective judgments. General well‐being is exclusively an expression of the individual's subjective experience and is based on his or her own qualitative evaluation of well‐being in relation to condition, treatments, and experiences. Health is according to the proposed definition, judged both objectively (signs) and subjectively (symptoms). Apart from health and well‐being, there is also reason to include objectively registrable factors at the welfare level (external factors) such as the consumption of medicines, number of days in hospital, length of sick leave, need of in‐home care, etc. This review is an attempt to elucidate the effects of antihypertensive pharmacotherapy on the patient's general well‐being. The topic will be discussed from several points of views (e.g., aims of antihypertensive treatment, occurrence of symptoms in the population, compliance with prescribed treatment, symptom inventories, the concept of quality of life).
No takes yet. Share an insight, caveat, or question.
C Dahlöf (1991) conducted a review in Hypertension. Antihypertensive pharmacotherapy was evaluated on General well-being and quality of life. Antihypertensive pharmacotherapy effects on patient general well-being and quality of life are reviewed across dimensions of health, subjective well-being, and external welfare factors.
Synapse has enriched 10 related papers. Consider them for comparative context: